All autopsies

// STARTUP COMPARISON

Theranos vs Ynsect

Theranos failed in 2018 due to Fraud. Ynsect failed in 2024 due to Unit Economics. Different causes, different sectors, different eras — but the same simulation outcome.

METRIC🔥 Theranos🔥 Ynsect
SectorBiotechBiotech
CountryUSAFrance
Founded20032011
Died20182024
Raised$945M€450M
Peak$9B valuation€1.7B valuation (2021)
Primary CauseFraudUnit Economics

// WHY EACH FAILED

🔥 Theranos
Fraud
Theranos failed because its Edison blood-testing device never worked. The company raised $945M while falsifying results using conventional machines. A 2015 Wall Street Journal investigation by John Carreyrou exposed the fraud. Elizabeth Holmes was convicted in January 2022 and sentenced to 11 years in prison.
// LESSON
The product must work. "Fake it till you make it" ends at the FDA boundary. No amount of narrative replaces a working device.
🔥 Ynsect
Unit Economics
Ynsect built vertical farms to breed mealworms for animal feed — positioning it at the intersection of sustainability, food security, and deep tech. It raised €450M and reached a €1.7B valuation. The problem was unit economics: its €200M flagship farm in Amiens required 18 months to reach full capacity and even at full capacity produced mealworm protein at €4/kg — vs. soybean meal at €0.45/kg. The 9× cost premium was not offset by sustainability positioning in commodity feed markets. Unable to achieve cost parity, Ynsect entered court-ordered restructuring (redressement judiciaire) in February 2024.
// LESSON
Sustainability is not a price premium in commodity markets. Animal feed buyers optimize for cost per gram of protein. If your insect protein costs 9× soybean meal, no amount of ESG storytelling closes that gap at B2B scale.

// EXPLORE FURTHER